Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: Why, who and how long?

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 126, Issue 2, 2006, Pages 146-154

  Kaufmann, Manfred ^a   Rody, Achim ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast cancer; Recurrence risk

Indexed keywords

AROMATASE INHIBITOR; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ARTHRALGIA; ARTHRITIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLD SWEAT; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG SAFETY; ENDOMETRIUM CANCER; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; LUNG EMBOLISM; MENSTRUATION DISORDER; METASTASIS; MYALGIA; NIGHT SWEAT; OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; REVIEW; STROKE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 33646815684     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.03.006     Document Type: Review

References (45)

1. Guarneri V., and Franco C.P. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 31 Suppl. 1 (2004) S149-S161
2. Tyczynski J.E., Plesko I., Aareleid T., et al. Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. Int J Cancer 112 (2004) 1056-1064
3. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 (1998) 1451-1467
5. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320 (1989) 479-484
6. Imaginis Corporation. Imaginis website. Available at: http://imaginis.com/. Accessed April 6, 2005.
7. Haynes B.P., Dowsett M., Miller W.R., Dixon J.M., and Bhatnagar A.S. The pharmacology of letrozole. J Steroid Biochem Mol Biol 87 (2003) 35-45
8. Choueiri T.K., Alemany C.A., Abou-Jawde R.M., and Budd G.T. Role of aromatase inhibitors in the treatment of breast cancer. Clin Ther 26 (2004) 1199-1214
9. Szymczak J., Milewicz A., Thijssen J.H., Blankenstein M.A., and Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. Steroids 63 (1998) 319-321
10. Goss P.E. Breast cancer prevention - clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 86 (2003) 487-493
11. Smith I.E. Aromatase inhibitors-extending the benefits of adjuvant therapy beyond tamoxifen. Breast 13 Suppl. 1 (2004) S3-S9
12. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
13. Horwitz KB. Bringing estrogen receptors under control [commentary]. Available at: http://breast-cancer-research.com/content/1/1/5. Accessed April 6, 2005.
14. Theobald A.J. Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team. Int J Clin Pract 54 (2000) 665-669
15. Day R., Ganz P.A., Costantino J.P., Cronin W.M., Wickerham D.L., and Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17 (1999) 2659-2669
16. Fisher B., Dignam J., Bryant J., and Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
17. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
18. Hortobagyi G.N., Kau S.-W., Buzdar A.U., et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?. J Clin Oncol 22 Suppl. 14 (2004) Abstract 585
19. Chia S.K., Speers C.H., Bryce C.J., Hayes M.M., and Olivotto I.A. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22 (2004) 1630-1637
20. Ravdin P.M., and Davis G.J. A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen. Clin Breast Cancer 5 (2004) 313-316
21. Kennecke H, Speers C, Chia S, et al. 10 year event free survival in postmenopausal women with early stage breast cancer during the second five years of tamoxifen. Presented at the 27th Annual San Antonio Breast Cancer Symposium. December 2004. Abstract 1049.
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
23. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 18 (2000) 3748-3757
24. Buzdar A., Jonat W., Howell A., et al., Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83 (1998) 1142-1152
25. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase-inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 (1998) 453-461
26. Kaufmann M., Bajetta E., Dirix L.Y., et al., The Exemestane Study Group. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double -blind trial. J Clin Oncol 18 (2000) 1399-1411
27. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 19 (2001) 2596-2606
28. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to Tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18 (2000) 3758-3767
29. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802 Epub October 9, 2003
30. Howell A., Cuzick J., Baum M., et al., ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
31. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
32. Janicke F. Are all aromatase inhibitors the same? A review of the current evidence. Breast 13 Suppl. 1 (2004) S10-S18
33. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 (2002) 751-757
34. Rose C., Vtoraya O., Pluzanska A., et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39 (2003) 2318-2327
35. Brodie A. Aromatase inhibitor development and hormone therapy: a perspective. Semin Oncol 30 4 Suppl. 14 (2003) 12-22
36. Brodie A., Jelovac D., and Long B.J. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin Cancer Res 9 (2003) 455S-459S
37. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003) 2101-2109
38. Goss P.E., Ingle J.N., Martino S., et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 22 Suppl. 14 (2004) Abstract 847
39. Whelan T., Goss P., Ingle J., et al. Assessment of quality of life (QoL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. J Clin Oncol 22 Suppl. 14S (2004) Abstract 517
40. Karnon J., Johnston S.R.D., Delea T.E., et al. Cost-effectiveness of extended adjuvant letrozole after five years of tamoxifen in postmenopausal early breast cancer. J Clin Oncol 22s Suppl. 14S (2004) Abstract 6044
41. Earle C.C., Chapman R.H., Baker C.S., et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18 (2000) 3302-3317
42. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report. J Clin Oncol 23 (2005) 619-629 Epub November 15, 2004
43. National Comprehensive Cancer Network. Clinical practice guidelines in oncology - Version 1.2005. © 2005 National Comprehensive Cancer Network, Inc. J Natl Compr Cancer Network 2005. Available at: http://www.nccn.org/professionals/physician_gls/license_agreement.asp. Accessed June 15, 2005.
44. Medscape Hematology-Oncology. 2004. Expert interview: Update on aromatase inhibitors in the extended adjuvant setting: a Canadian thought-leader perspective from Paul E. Goss, MD, PhD. Available at: http://www.medscape.com/viewarticle/482102. Accessed June 15, 2005.
45. Hillner B.E., Ingle J.N., Chlebowski R.T., et al., American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057 Epub September 9, 2003. Erratum in: J Clin Oncol 2004; 22: 1351